These promising results were refuted by the study of Delville et al. who prospectively administered abatacept or belatacept (a B7-1 blocker with a 2-fold higher affinity for B7-1) to nine consecutive patients with recurrent FSGS after transplant. This evidence concerns the gene CD80 and focal segmental glomerulosclerosis.